Development Programs

Advancing Novel Treatments for Patients with Muscle Disease

Kate Therapeutics has established a portfolio of muscle disease programs by selecting targets based on a number of criteria, including unmet medical need, technical feasibility for replacing or editing disease-causing mutations, and time required to advance the drug candidate into and through clinical trials.

Discovery

Lead Optimization

Nonclinical Development

Clinical Development

WW Rights

Nonclinical Development - Partnered with Astellas

65%

Myotonic Dystrophy Type 1

Lead Optimization

40%

Facioscapulohumeral Dystrophy

Lead Optimization

40%

Genetic Muscular Dystrophy

Lead Optimization

30%

Genetic Cardiomyopathy

Discovery

20%

Kate Therapeutics is a privately-held company with experienced leadership, a world-class scientific advisory team, and leading investor partners.